Terms: = Ovarian cancer AND CDKN2A, CDK4I, 1029, ENSG00000147889, P42771, p14, CMM2, ARF, TP16, p16, MTS1, p19, p16INK4a, INK4a, CDKN2, p16INK4, p14ARF, MLM, INK4 AND Treatment
110 results:
1. Predictive and prognostic biomarkers in female genital tract tumours: an update highlighting their clinical relevance and practical issues.
Wong RW; Cheung ANY
Pathology; 2024 Mar; 56(2):214-227. PubMed ID: 38212229
[TBL] [Abstract] [Full Text] [Related]
2. The Role of Cellular Senescence in Cyclophosphamide-Induced Primary ovarian Insufficiency.
Xu Z; Takahashi N; Harada M; Kunitomi C; Kusamoto A; Koike H; Tanaka T; Sakaguchi N; Urata Y; Wada-Hiraike O; Hirota Y; Osuga Y
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139022
[TBL] [Abstract] [Full Text] [Related]
3. P53 and TLR4 expression are prognostic markers informing progression free survival of advanced stage high grade serous ovarian cancer.
Bates M; Mullen D; Lee E; Costigan D; Heron EA; Kernan N; Barry-O'Crowley J; Martin C; Keegan H; Malone V; Brooks RD; Brooks DA; Logan JM; Martini C; Selemidis S; McFadden J; O'Riain C; Spillane CD; Gallagher MF; McCann A; O'Toole S; O'Leary JJ
Pathol Res Pract; 2024 Jan; 253():155020. PubMed ID: 38103365
[TBL] [Abstract] [Full Text] [Related]
4. Mechanisms of carboplatin- and paclitaxel-dependent induction of premature senescence and pro-cancerogenic conversion of normal peritoneal mesothelium and fibroblasts.
Rutecki S; Pakuła-Iwańska M; Leśniewska-Bocianowska A; Matuszewska J; Rychlewski D; Uruski P; Stryczyński Ł; Naumowicz E; Szubert S; Tykarski A; Mikuła-Pietrasik J; Książek K
J Pathol; 2024 Feb; 262(2):198-211. PubMed ID: 37941520
[TBL] [Abstract] [Full Text] [Related]
5. Adult granulosa cell tumor of the testis with malignant tendency: A case report with genetic analysis using high-throughput sequencing.
Deng L; Zeng J; Qiu JF; Yang LH; Ma J
Medicine (Baltimore); 2023 Aug; 102(32):e34523. PubMed ID: 37565864
[TBL] [Abstract] [Full Text] [Related]
6. The usefulness of p16 and COX-2 expression on the prediction of progression to endometrial cancer.
Kalkan HE; Akman L; Serin G; Terek MC; Zekioglu O; Ozsaran AA
Histol Histopathol; 2024 May; 39(5):565-571. PubMed ID: 37503793
[TBL] [Abstract] [Full Text] [Related]
7. Unilateral ovarian recurrence 5 years after hysterectomy for microinvasive squamous cervical cancer stage IA1: a rare case report.
Tong L; Wu L
BMC Womens Health; 2023 Jul; 23(1):350. PubMed ID: 37393247
[TBL] [Abstract] [Full Text] [Related]
8. Uterine choriocarcinoma coexistence with endometroid adenocacinoma: a case report and literature review.
Bai L; Chen Y; Han L; Zheng A; Mo X
BMC Womens Health; 2023 May; 23(1):252. PubMed ID: 37165420
[TBL] [Abstract] [Full Text] [Related]
9. Loss of p16 does not protect against premature ovarian insufficiency caused by alkylating agents.
Liu F; Wan Q; Liu P; Miao D; Dai X; Chen L
BMC Pregnancy Childbirth; 2023 Mar; 23(1):151. PubMed ID: 36890528
[TBL] [Abstract] [Full Text] [Related]
10. Immunohistochemical and molecular analysis of an α-fetoprotein-producing cervical adenocarcinoma with clear cell morphology.
Kuriyama S; Yano M; Kusaba T; Zaitsu S; Nishida H; Yasuda M; Nasu K
Med Mol Morphol; 2023 Mar; 56(1):20-27. PubMed ID: 36183278
[TBL] [Abstract] [Full Text] [Related]
11. Somatic genomic landscape of East Asian epithelial ovarian carcinoma and its clinical implications from prospective clinical sequencing: A Korean Gynecologic Oncology Group study (KGOG 3047).
Sa JK; Kim J; Kang S; Kim SW; Song T; Shim SH; Choi MC; No JH; Song JY; Kim D; Kim YM; Kim JH; Lee JW
Int J Cancer; 2022 Oct; 151(7):1086-1097. PubMed ID: 35666535
[TBL] [Abstract] [Full Text] [Related]
12. [Primary ovarian squamous cell carcinoma: clinicopathological features and prognostic analysis of fifteen cases].
Xi Y; Zhang ML; He C; Cheng GP; Jin JY; Fang XH; Zhu T; Su D
Zhonghua Bing Li Xue Za Zhi; 2022 Apr; 51(4):332-337. PubMed ID: 35359045
[No Abstract] [Full Text] [Related]
13. Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib treatment Across Histologic Tumor Types.
van der Wijngaart H; Hoes LR; van Berge Henegouwen JM; van der Velden DL; Zeverijn LJ; Roepman P; van Werkhoven E; de Leng WWJ; Jansen AML; Mehra N; Robbrecht DGJ; Labots M; de Groot DJA; Hoeben A; Hamberg P; Gelderblom H; Voest EE; Verheul HMW
Clin Cancer Res; 2021 Nov; 27(22):6106-6114. PubMed ID: 34475104
[TBL] [Abstract] [Full Text] [Related]
14. lncRNA cdkn2a-AS1 facilitates tumorigenesis and progression of epithelial ovarian cancer via modulating the SOSTDC1-mediated BMP-SMAD signaling pathway.
Zhao Q; Dong D; Chu H; Man L; Huang X; Yin L; Zhao D; Mu L; Gao C; Che J; Liu Q
Cell Cycle; 2021 Jun; 20(12):1147-1162. PubMed ID: 34110955
[TBL] [Abstract] [Full Text] [Related]
15. Trichodermin Induces G0/G1 Cell Cycle Arrest by Inhibiting c-Myc in ovarian cancer Cells and Tumor Xenograft-Bearing Mice.
Gao Y; Miles SL; Dasgupta P; Rankin GO; Cutler S; Chen YC
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34065149
[TBL] [Abstract] [Full Text] [Related]
16. ARID1A genomic alterations driving microsatellite instability through somatic MLH1 methylation with response to immunotherapy in metastatic lung adenocarcinoma: a case report.
Durán M; Faull I; Lastra E; Laes JF; Rodrigo AB; Sánchez-Escribano R
J Med Case Rep; 2021 Feb; 15(1):89. PubMed ID: 33608032
[TBL] [Abstract] [Full Text] [Related]
17. Multiomics Characterization of Low-Grade Serous ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic Vulnerability.
Shrestha R; Llaurado Fernandez M; Dawson A; Hoenisch J; Volik S; Lin YY; Anderson S; Kim H; Haegert AM; Colborne S; Wong NKY; McConeghy B; Bell RH; Brahmbhatt S; Lee CH; DiMattia GE; Le Bihan S; Morin GB; Collins CC; Carey MS
Cancer Res; 2021 Apr; 81(7):1681-1694. PubMed ID: 33441310
[TBL] [Abstract] [Full Text] [Related]
18. Azidothymidine (AZT) Inhibits Proliferation of Human ovarian cancer Cells by Regulating Cell Cycle Progression.
Hsieh Y; Tseng JJ
Anticancer Res; 2020 Oct; 40(10):5517-5527. PubMed ID: 32988875
[TBL] [Abstract] [Full Text] [Related]
19. A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer.
Bantie L; Tadesse S; Likisa J; Yu M; Noll B; Heinemann G; Lokman NA; Ricciardelli C; Oehler MK; Beck A; Pradhan R; Milne R; Albrecht H; Wang S
Gynecol Oncol; 2020 Dec; 159(3):827-838. PubMed ID: 32958271
[TBL] [Abstract] [Full Text] [Related]
20. Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities.
Cheasley D; Nigam A; Zethoven M; Hunter S; Etemadmoghadam D; Semple T; Allan P; Carey MS; Fernandez ML; Dawson A; Köbel M; Huntsman DG; Le Page C; Mes-Masson AM; Provencher D; Hacker N; Gao Y; Bowtell D; deFazio A; Gorringe KL; Campbell IG
J Pathol; 2021 Jan; 253(1):41-54. PubMed ID: 32901952
[TBL] [Abstract] [Full Text] [Related]
[Next]
